To include your compound in the COVID-19 Resource Center, submit it here.

Akcea submits MAA for volanesorsen to treat familial chylomicronemia syndrome

Akcea Therapeutics Inc. (NASDAQ:AKCA) submitted an MAA to EMA for volanesorsen (IONIS-APOCIIIRx, ISIS

Read the full 137 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE